At VivaTech 2026, Taiwan-Based MaiAgent Says Enterprises Should Stop Building RAG and AI Agent Systems From Scratch
TAIPEI and PARIS, June 19, 2026 /PRNewswire/ -- At VivaTech 2026, MaiAgent, a Taiwan-based enterprise AI agent platform, said it is helping enterprises worldwide advance their AI transformation by moving AI agents from proof of concept to production...
Cohesity Secures Earliest Invented Patent in the Industry for GenAI Retrieval-Augmented Generation (RAG) Platform Built on Secondary Data
Patent validates Cohesity's architectural lead in applying GenAI to secondary data to unlock AI without data movement SINGAPORE, June 3, 2026 /PRNewswire/ -- Cohesity, a leader in AI-powered data security, today announced that the U.S. Patent and...
Ractigen Therapeutics Presents Positive Phase I Data for RAG-17 in SOD1-ALS at the 2026 AAN Annual Meeting, Demonstrating 81% Reduction in Neurofilament Light Chain
— Single intrathecal dose of SCAD-siRNA therapeutic RAG-17 yields favorable safety profile and profound, durable biomarker reductions — — Preliminary data from 180 mg cohort shows trends of clinical stabilization (ALSFRS-R) — — Phase II trial is now...
Ractigen Therapeutics Announces China NMPA IND Approval for Phase II Clinical Trial of saRNA Therapy RAG-01 in Non-Muscle Invasive Bladder Cancer
NANTONG, China, March 19, 2026 /PRNewswire/ -- Ractigen Therapeutics, a pioneering clinical-stage biotechnology company developing innovative small activating RNA (saRNA) therapeutics, today announced that China's National Medical Products...
F5 2026 Solution Day Kicks Off in Hong Kong, Leading the Way in AI and Multicloud Era with Digital Resilience
HONG KONG, March 18, 2026 /PRNewswire/ -- On March 18, 2026, F5 hosted its 2026 Solution Day in Hong Kong, centered on the theme, "Digital Resilience in the AI and Multicloud Era." As cloud and SaaS failures reach a critical inflection point, the...
WhaleFlux Signals a Shift Toward Architecting Enterprise AI Systems as Enterprise AI Enters a New Phase in 2026
SAN FRANCISCO, Jan. 21, 2026 /PRNewswire/ -- As enterprise AI adoption moves beyond experimentation and into production, the industry is entering a new phase where system reliability, governance, and long-term operability matter more than model...
Ractigen Therapeutics Announces First Patient Dosed in Phase II Clinical Trial of RAG-17 for SOD1-ALS
NANTONG, China, Jan. 13, 2026 /PRNewswire/ -- Ractigen Therapeutics is pleased to announce that the first patient has been dosed in the Phase II clinical trial of RAG-17, an innovative siRNA therapy targeting SOD1-mutated amyotrophic lateral...
Ractigen Therapeutics Doses First Patient in IIT Study of RAG-18, a Potential Game-Changing saRNA Therapeutic for Duchenne Muscular Dystrophy
NANTONG, China, Dec. 12, 2025 /PRNewswire/ -- Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced the successful dosing of the first patient in its investigator-initiated trial (IIT) of RAG-18...
Ractigen Therapeutics Doses First Patient in IIT Study of RAG-18 for Duchenne Muscular Dystrophy
NANTONG, China, Dec. 12, 2025 /PRNewswire/ -- Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced the successful dosing of the first patient in its investigator-initiated trial (IIT) of RAG-18...
Ractigen's RAG-17 ALS Data Shines at AAN 2025: Earns Top Award, Phase I Advances
Final results from an Investigator-Initiated Trial presented for the first time, demonstrating favorable safety, significant target engagement, and encouraging clinical & biomarker signals Abstract honored with prestigious "Abstracts of...